Notice of Change to Key Dates for RFA-FD-17-006 "Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R 30)"

Notice Number: NOT-FD-17-011

Key Dates
Release Date: June 7, 2017

Related Announcements
RFA-FD-17-006

Issued by
U.S. Food and Drug Administration (FDA)

Purpose

The purpose of this Notice is to change the Due Date for RFA-FD-17-006.

Application Due Date(s)

July 24, 2017, by 11:59 PM Eastern Time.
RFAs that must be reviewed on a compressed timeline and want to prohibit late applications must add the following text prior to approval for publication, here and below.
“No late applications will be accepted for this Funding Opportunity Announcement.”

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. 

Late applications will not be accepted for this FOA.

.

Inquiries

Please direct all inquiries to:

Shashi Malhotra
U.S. Food and Drug Administration (FDA)
Telephone:  240-402-7592
Email: Shashi.Malhotra@fda.hhs.gov